Although there were fewer adverse skin events in the full dose combination of the two drugs compared with BRAF inhibitor monotherapy, the addition of trametinib increased pyrexia, interstitial lung disease, venous thromboembolism, gastrointestinal bleeding, and heart (cardiomyopathy, decreased left ventricular ejection fraction) or ocular (retinal vein occlusion, uveitis) toxicity (34, 35). The gene discussed is BRAF; the disease is retinal vein occlusion.